Opinion|Videos|July 8, 2024
EMERALD Study Design and Results for Elacestrant
Key opinion leaders examine the EMERALD trial, which evaluates the efficacy of elacestrant in patients with HR+ HER2- metastatic breast cancer, focusing on the subgroup analysis of patients with visceral metastases, and explore how the trial's design and results have influenced their clinical practice.
Advertisement
Episodes in this series
- Please provide some background on the EMERALD trial evaluating elacestrant in HR+ HER2- mBC as well as subgroup data in patients with visceral metastases (
Shah et al. J Clin Oncol. 2024 )
- How have the EMERALD trial impacted your use of Elacestrant in clinical practice, particularly in terms of patients’ selection and treatment sequencing?
- What are your impressions of the overall and subgroup data from EMERALD? Does it expand the ideal patient population for elacestrant?
- For a patient with metastatic breast cancer to bones, liver, and lungs who has an ESR1 mutation, how does this inform treatment selection between continuing endocrine therapy versus switching to other targeted agents or chemotherapy?
- Would elacestrant be an ideal next line treatment for this patient?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
3
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5